JOHN S. MACDONALD, M.D.; PHILIP S. SCHEIN, M.D.; PAUL V. WOOLLEY, M.D.; TARILYN SMYTHE, B.S.; WINSTON UENO, M.D.; DANIEL HOTH, M.D.; FREDERICK SMITH, M.D.; MICHEL BOIRON, M.D.; CHRISTIAN GISSELBRECHT, M.D.; RENE BRUNET, M.D.; CLAUDE LAGARDE, M.D.
Sixty-two patients with advanced measurable gastric cancer were treated with a combination chemotherapy program of 5-fluorouracil, doxorubicin, and mitomycin (FAM). Forty-two percent of patients achieved an objective partial response. The median duration of remission was 9 months and the median survival for responding patients, 12.5 months. The median survival for nonresponding patients was 3.5 months; all patients were dead by 8 months after initiation of therapy. The median survival of all 62 patients treated with FAM was 5.5 months. An analysis of possible prognostic variables including initial performance status, resectability of the primary gastric tumor, and histologic differentiation of the neoplasm failed to account for differences in patient response and survival. The FAM regimen was well tolerated, producing only moderate bone marrow suppression. These results show that patients with metastatic gastric cancer can be effectively palliated with FAM chemotherapy. The efficacy of this regimen should now be tested in patients with less advanced stages of this disease.
MACDONALD JS, SCHEIN PS, WOOLLEY PV, SMYTHE T, UENO W, HOTH D, et al. 5-Fluorouracil, Doxorubicin, and Mitomycin (FAM) Combination Chemotherapy for Advanced Gastric Cancer. Ann Intern Med. ;93:533–536. doi: 10.7326/0003-4819-93-4-533
Download citation file:
Published: Ann Intern Med. 1980;93(4):533-536.
Gastric Cancer, Gastroenterology/Hepatology, Gastrointestinal Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use